Tillotts Pharma AG is a dynamic and well-established European GI-focused pharmaceutical company, based in Ziefen close to Basel, Switzerland. Tillotts’ business operations are focused on the development, production and marketing of branded pharmaceutical products for the treatment of GI diseases, namely Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). The majority (81%) of Tillotts shares are owned by people who work for the company, the remainder being held by UCB Pharma SA.